Drug Profile


Alternative Names: SMOCL-9112

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Acebright Pharmaceuticals; Shanghai Institute of Materia Medica
  • Developer Shanghai Acebright Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 22 Mar 2017 Chemical structure information added
  • 01 Dec 2016 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease) in China (PO) (NCT02993913)
  • 30 Nov 2016 Shanghai Acebright Pharmaceuticals plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO, Tablet) (NCT02993913)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top